Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nodosis is a sodium bicarbonate-based pharmaceutical product developed and marketed by Steadfast Medishield (now Steadfast Limited) for renal care and electrolyte management. As an alkalizing agent, it provides bicarbonate ions that neutralize hydrogen ion concentration in the blood and urine, effectively treating metabolic acidosis and promoting urinary alkalinization. It is specifically indicated for patients with chronic kidney disease (CKD) to manage acid-base imbalances, as well as for electrolyte replacement in conditions like severe diarrhea. The product is available in various formulations, including standard tablets (500mg), double-strength (DS) tablets (1000mg), enteric-coated (GST) tablets for gastric protection, oral suspension, and granules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nodosis.